

Olivier Mir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5631442/publications.pdf>

Version: 2024-02-01

103
papers

3,968
citations

159585

30
h-index

128289

60
g-index

105
all docs

105
docs citations

105
times ranked

4682
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986.		30
2	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clinical Cancer Research, 2022, 28, 1672-1679.	7.0	18
3	Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy " brachytherapy association. Oral Oncology, 2022, 125, 105715.	1.5	1
4	Lack of Prognostic Value of <i>CTNNB1</i> Mutation Profile in Desmoid-Type Fibromatosis. Clinical Cancer Research, 2022, 28, 4105-4111.	7.0	11
5	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nature Medicine, 2022, 28, 1224-1231.	30.7	38
6	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 "CaboGIST"™. Acta OncolÁgica, 2022, 61, 663-668.	1.8	1
7	Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma. Cancer Medicine, 2021, 10, 230-236.	2.8	7
8	Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?. Immunotherapy, 2021, 13, 91-93.	2.0	1
9	Nurse navigators"™ telemonitoring for cancer patients with COVID-19: a French case study. Supportive Care in Cancer, 2021, 29, 4485-4492.	2.2	10
10	The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma. Oncologist, 2021, 26, 389-396.	3.7	8
11	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist, 2021, 26, e639-e649.	3.7	29
12	Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents. Cancers, 2021, 13, 1238.	3.7	14
13	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer, 2021, 145, 132-142.	2.8	75
14	Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis"™Response. Clinical Cancer Research, 2021, 27, 2120-2120.	7.0	0
15	Targeting the VEGF Pathway in Osteosarcoma. Cells, 2021, 10, 1240.	4.1	24
16	Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. Targeted Oncology, 2021, 16, 485-492.	3.6	3
17	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. European Journal of Cancer, 2021, 150, 108-118.	2.8	16
18	TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfILER Precision Medicine Trials. Cancers, 2021, 13, 3362.	3.7	6

#	ARTICLE	IF	CITATIONS
19	Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?. <i>Clinical and Translational Radiation Oncology</i> , 2021, 29, 79-84.	1.7	1
20	Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. <i>JCO Oncology Practice</i> , 2021, 17, e1311-e1317.	2.9	4
21	Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC. <i>Pharmaceuticals</i> , 2021, 14, 927.	3.8	3
22	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	1.6	56
23	Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of <i>CTNNB1</i> Mutational Status. <i>Clinical Cancer Research</i> , 2020, 26, 6277-6283.	7.0	18
24	Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. <i>Cancers</i> , 2020, 12, 3746.	3.7	6
25	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3758.	3.7	4
26	How to Design a Remote Patient Monitoring System? A French Case Study. <i>BMC Health Services Research</i> , 2020, 20, 434.	2.2	20
27	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 <i>â€”CaboGISTâ€™</i> . <i>European Journal of Cancer</i> , 2020, 134, 62-74.	2.8	42
28	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase I trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	10.7	186
29	Endometriosis. <i>New England Journal of Medicine</i> , 2020, 383, 193-194.	27.0	6
30	Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103029.	4.4	35
31	A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102889.	4.4	23
32	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. <i>European Journal of Cancer</i> , 2020, 128, 119-128.	2.8	50
33	Letter: Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era. <i>Neurosurgery</i> , 2020, 86, E480-E482.	1.1	3
34	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 446-455.	10.7	182
35	Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?. <i>European Journal of Cancer</i> , 2020, 128, 103-106.	2.8	7
36	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. <i>European Journal of Cancer</i> , 2020, 126, 45-55.	2.8	9

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers. <i>European Journal of Cancer</i> , 2020, 128, 107-118.	2.8	36
38	Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 112-124.	4.4	11
39	Basic Knowledge in Soft Tissue Sarcoma. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1255-1261.	2.0	63
40	The impact of the Paris terrorist attacks on the mental health of resident physicians. <i>BMC Psychiatry</i> , 2019, 19, 79.	2.6	16
41	Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1479-1485.	7.0	63
42	Clinical Activity of Sunitinib and Regorafenib in Endometriosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2591-2593.	3.0	2
43	A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. <i>Cancer Treatment Reviews</i> , 2019, 72, 37-44.	7.7	27
44	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 120-133.	10.7	222
45	Everolimus induced mood changes in breast cancer patients: a case-control study. <i>Investigational New Drugs</i> , 2018, 36, 503-508.	2.6	9
46	Interventional radiology: Role in the treatment of sarcomas. <i>European Journal of Cancer</i> , 2018, 94, 148-155.	2.8	22
47	Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. <i>Investigational New Drugs</i> , 2018, 36, 156-162.	2.6	19
48	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	3.7	62
49	Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2018, 103, 88-97.	2.8	22
50	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018, 99, 28-36.	2.8	13
51	Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. <i>BMC Medicine</i> , 2017, 15, 78.	5.5	143
52	<sc>REGOSARC</sc>: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma: A quality-adjusted time without symptoms of progression or toxicity analysis. <i>Cancer</i> , 2017, 123, 2294-2302.	4.1	38
53	PD-1 inhibition in bone sarcoma and soft-tissue sarcoma. <i>Lancet Oncology</i> , The, 2017, 18, 1430-1431.	10.7	6
54	Colchicine is an active treatment for everolimus-induced oral ulcers. <i>European Journal of Cancer</i> , 2017, 87, 209-211.	2.8	4

#	ARTICLE	IF	CITATIONS
55	Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. <i>Investigational New Drugs</i> , 2017, 35, 247-249.	2.6	8
56	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. <i>Scientific Reports</i> , 2017, 7, 17917.	3.3	10
57	Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. <i>British Journal of Cancer</i> , 2017, 117, 1787-1797.	6.4	30
58	Individualized Pazopanib Dosing Letter. <i>Clinical Cancer Research</i> , 2016, 22, 6298-6298.	7.0	4
59	Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 632-641.	10.7	98
60	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. <i>European Journal of Cancer</i> , 2016, 66, 75-82.	2.8	5
61	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1732-1742.	10.7	200
62	Hepatitis B reactivation during everolimus treatment. <i>Acta Oncologica</i> , 2016, 55, 1505-1506.	1.8	4
63	Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). <i>Oncotarget</i> , 2016, 7, 73984-73994.	1.8	23
64	Pharmacokinetics of Systemic Anticancer Therapies During Pregnancy. , 2016, , 55-70.		0
65	Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 231-236.	7.3	8
66	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 312-319.	10.7	78
67	Nilotinib versus imatinib for GIST. <i>Lancet Oncology</i> , The, 2015, 16, e311.	10.7	2
68	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2797-2802.	1.6	153
69	Gynecologic Cancers in Pregnancy: Guidelines of a Second International Consensus Meeting. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 394-403.	2.5	198
70	Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. <i>Investigational New Drugs</i> , 2014, 32, 569-572.	2.6	17
71	Results of the MARS study on the management of antiangiogenics™ renovascular safety in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 466-466.	1.6	0
72	Results of the MARS study on the management of antiangiogenics™ renovascular safety in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 394-394.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Results of the MARS study on the management of antiangiogenics™ renovascular safety in ovarian cancer.. Journal of Clinical Oncology, 2013, 31, 5567-5567.	1.6	5
74	Results of the MARS study on the management of antiangiogenics™ renovascular safety in breast cancer.. Journal of Clinical Oncology, 2013, 31, e12504-e12504.	1.6	1
75	Taxanes during Pregnancy: Probably Safe, but Still to Be Optimized. Oncology, 2012, 83, 239-240.	1.9	26
76	Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma. Anti-Cancer Drugs, 2012, 23, 745-748.	1.4	16
77	Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anti-Cancer Drugs, 2012, 23, 739-744.	1.4	18
78	Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Lung Cancer, 2012, 77, 104-109.	2.0	16
79	Saturable absorption of sorafenib in patients with solid tumors: a population model. Investigational New Drugs, 2012, 30, 1991-2000.	2.6	42
80	Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 2046-2049.	2.6	95
81	Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. Supportive Care in Cancer, 2012, 20, 2235-2239.	2.2	8
82	Increased evidence for use of chemotherapy in pregnancy. Lancet Oncology, The, 2012, 13, 852-854.	10.7	14
83	Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. American Journal of Obstetrics and Gynecology, 2012, 207, 514.e1-514.e7.	1.3	31
84	Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Medical Oncology, 2012, 29, 2793-2799.	2.5	40
85	Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. Cancer Chemotherapy and Pharmacology, 2012, 69, 357-367.	2.3	32
86	Treatment of bevacizumab-induced hypertension by amlodipine. Investigational New Drugs, 2012, 30, 702-707.	2.6	53
87	First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas.. Journal of Clinical Oncology, 2012, 30, 2557-2557.	1.6	2
88	Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e37563.	2.5	252
89	Management of antiangiogenics™ renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study.. Journal of Clinical Oncology, 2012, 30, 5067-5067.	1.6	0
90	Management of antiangiogenics™ renovascular safety in breast cancer subgroup and intermediate results of the MARS study.. Journal of Clinical Oncology, 2012, 30, 1095-1095.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2011, 47, 515-519.	2.8	72
92	Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents. <i>Investigational New Drugs</i> , 2011, 29, 716-718.	2.6	13
93	Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. <i>Targeted Oncology</i> , 2011, 6, 253-258.	3.6	117
94	An Observational Study of Bevacizumab-Induced Hypertension as a Clinical Biomarker of Antitumor Activity. <i>Oncologist</i> , 2011, 16, 1325-1332.	3.7	70
95	Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1059-1063.	2.3	24
96	Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 99-101.	2.4	49
97	Breast cancer in pregnancy: Recommendations of an international consensus meeting. <i>European Journal of Cancer</i> , 2010, 46, 3158-3168.	2.8	238
98	Cisplatin as a cornerstone of modern chemotherapy. <i>Lancet Oncology</i> , The, 2009, 10, 304.	10.7	7
99	Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. <i>Anti-Cancer Drugs</i> , 2009, 20, 105-108.	1.4	12
100	Use of platinum derivatives during pregnancy. <i>Cancer</i> , 2008, 113, 3069-3074.	4.1	120
101	Ectopic pregnancy in a breast cancer patient receiving trastuzumab. <i>Reproductive Toxicology</i> , 2008, 25, 286-288.	2.9	18
102	Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma. <i>Aids</i> , 2008, 22, 1237-1239.	2.2	7
103	Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms. <i>Gynecologic Oncology</i> , 2007, 106, 622-625.	1.4	2